Petrelintide
Medium EvidenceA long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo.
What It Is
Petrelintide (formerly ZP8396) is a once-weekly, long-acting amylin receptor agonist developed by Zealand Pharma and co-developed and co-commercialized with Roche (and its U.S. subsidiary Genentech) under a 2025 global collaboration and licensing agreement. Amylin is a pancreatic hormone co-secreted with insulin that reduces appetite, slows gastric emptying, and promotes satiety; petrelintide is engineered as a synthetic analog to recreate this effect with a dosing schedule suitable for once-weekly subcutaneous injection. In the Phase 2 ZUPREME-1 dose-finding trial, which enrolled 493 people living with overweight and obesity (mean baseline BMI ~37 kg/m2), petrelintide produced up to 10.7% mean weight loss from baseline at week 42 using the efficacy estimand, versus 1.7% for placebo, with statistically significant and clinically meaningful weight loss across all five active treatment arms after 28 weeks. A defining feature of the results was tolerability: rates of gastrointestinal adverse events were comparable to placebo, and the proportion of participants who experienced vomiting was actually lower on petrelintide than on placebo. Zealand and Roche reported the positive topline Phase 2 results on March 5, 2026, with full data including a nine-week safety follow-up slated for a 2026 scientific conference and Phase 3 initiation expected later in 2026. Zealand confirmed it will present additional petrelintide data at the American Diabetes Association (ADA) 2026 Scientific Sessions (June 5-8, New Orleans), where the ZUPREME-1 readout was selected for the ADA Official Press Program. At the ADA 2026 Scientific Sessions (June 5–8, New Orleans), Zealand and Roche presented full ZUPREME-1 data revealing a comprehensive cardiometabolic benefit profile: petrelintide reduced waist circumference by 7.9–10.8 cm versus 4.3 cm with placebo, high-sensitivity C-reactive protein (hsCRP) by 17–41% versus 6% with placebo, and triglycerides by 12–21% versus 9% with placebo — meaningful improvements in cardiovascular risk factors on top of the primary weight-loss endpoint. Zealand confirmed Phase 3 initiation is expected in H2 2026; topline results from ZUPREME-2 (petrelintide in obesity + type 2 diabetes) are also expected in H2 2026. Petrelintide is positioned as a potential foundational therapy for obesity, both as a standalone amylin agent emphasizing quality and tolerability of weight loss and as a backbone for combination with incretin drugs such as enicepatide (Roche/Genentech's GLP-1/GIP agonist).
Regulatory Status
Full Phase 2 ZUPREME-1 data presented at ADA 2026 Scientific Sessions (June 5–8, 2026) with cardiometabolic secondary endpoints confirmed. Phase 3 initiation expected H2 2026. ZUPREME-2 (T2D + obesity) topline expected H2 2026. Not approved in any jurisdiction.
Effective: June 2026
View FDA SourceWhy Researchers Study It
Petrelintide is one of the most advanced standalone amylin analogs for obesity and is closely watched because its Phase 2 data pair double-digit weight loss with gastrointestinal tolerability comparable to placebo - a profile that contrasts with the GI burden often associated with GLP-1-based therapies. Researchers study it as both a potential foundational monotherapy and as a backbone for combination with incretin drugs, and because the Roche/Genentech partnership signals major commercial conviction in amylin biology as the next pillar of weight management.
Proposed Mechanisms
- Agonizes amylin receptors to reduce appetite and promote satiety
- Slows gastric emptying to prolong fullness after meals
- Long-acting design enables once-weekly subcutaneous dosing
- Aims to deliver weight loss with gastrointestinal tolerability comparable to placebo
- Positioned as a potential backbone for combination with incretin (GLP-1) therapies
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 2, ZUPREME-1) | 493 adults with overweight or obesity, mean baseline BMI ~37 kg/m2 | Up to 10.7% mean weight loss from baseline at week 42 (efficacy estimand) vs 1.7% placebo; significant weight loss across all five active arms at 28 weeks; GI adverse-event rates comparable to placebo | Source |
| Partnership / development | Zealand Pharma + Roche/Genentech global collaboration | 2025 co-development and co-commercialization agreement; full Phase 2 data and ADA 2026 presentation planned, with Phase 3 initiation expected later in 2026 | Source |
| Phase 2 full data (ADA 2026 presentation) | 42-week Phase 2 ZUPREME-1 in adults with overweight/obesity — full cardiovascular and body composition endpoints; presented at ADA 2026 Scientific Sessions, New Orleans, June 5–8, 2026 | Up to 10.7% mean weight loss vs 1.7% placebo at 42 weeks; waist circumference −7.9 to −10.8 cm vs −4.3 cm placebo; hsCRP −17–41% vs −6% placebo; triglycerides −12–21% vs −9% placebo; GI adverse events comparable to placebo; zero treatment discontinuations due to vomiting | Source |
Commonly Discussed Benefits
Researching Petrelintide? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Investigational; not approved in any jurisdiction
- Only Phase 2 efficacy and tolerability data reported to date; long-term outcomes unknown
- Full ZUPREME-1 data (including nine-week safety follow-up) not yet peer-reviewed/published
- Available only through clinical trial enrollment
- Not FDA-approved; not a compounding-eligible peptide
Comparisons
See how Petrelintide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Zealand Pharma announces positive Phase 2 results for petrelintide (Mar 5, 2026) PubMed
- [2] Roche announces positive Phase II results for petrelintide (Mar 5, 2026) PubMed
- [3] Zealand Pharma to Present Data at the ADA 2026 Scientific Sessions (May 27, 2026) PubMed
- [4] Petrelintide - Pipeline - Zealand Pharma PubMed
Keep researching in the app
- Log Petrelintide to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Cagrilintide
High EvidenceA long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.
Amycretin
Medium EvidenceA unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a.
MET-097i
Medium EvidenceAn ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials.
Dapiglutide
Medium EvidenceA long-acting, once-weekly dual GLP-1 and GLP-2 receptor agonist peptide (Zealand Pharma) developed for obesity, uniquely pairing GLP-1-driven weight loss with GLP-2 activation intended to improve intestinal barrier function and reduce obesity-related low-grade inflammation; development was paused in November 2025.
CT-388
Medium EvidenceAn investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism.
ALV-200
Low EvidenceALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing.
ASC39
Low EvidenceASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026.
MET-233i
Medium EvidenceMET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection.